A survey of physicians' treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries
{{output}}
Objective: Recombinant factor VIII and factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) were developed with an extended half-life (EHL) to improve the management of people with hemophilia A (PwHA) and B (PwHB), respectively. ... ...
